IQVIA (NYSE:IQV) Receives “Equal Weight” Rating from Morgan Stanley

IQVIA (NYSE:IQV)‘s stock had its “equal weight” rating reissued by stock analysts at Morgan Stanley in a research report issued on Wednesday, MarketBeat Ratings reports. They presently have a $200.00 target price on the medical research company’s stock, down from their previous target price of $225.00. Morgan Stanley’s price target indicates a potential upside of 11.71% from the company’s current price.

A number of other analysts have also recently commented on the company. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Mizuho set a $215.00 price target on IQVIA in a research report on Monday, February 23rd. Truist Financial lowered their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday, February 19th. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research report on Sunday. Finally, HSBC set a $210.00 price target on IQVIA in a research report on Wednesday, June 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, IQVIA has an average rating of “Moderate Buy” and an average target price of $222.56.

IQVIA Stock Up 0.4%

Shares of IQV stock opened at $179.04 on Wednesday. IQVIA has a 1-year low of $153.01 and a 1-year high of $247.04. The stock’s fifty day moving average price is $173.77 and its 200 day moving average price is $192.69. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The company has a market cap of $29.88 billion, a price-to-earnings ratio of 22.19, a price-to-earnings-growth ratio of 1.53 and a beta of 1.21.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the previous year, the firm posted $2.70 EPS. The firm’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, research analysts expect that IQVIA will post 11.6 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a stock buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

Hedge Funds Weigh In On IQVIA

Institutional investors and hedge funds have recently modified their holdings of the stock. Ameliora Wealth Management Ltd. acquired a new position in shares of IQVIA in the 4th quarter valued at about $25,000. International Assets Investment Management LLC acquired a new position in IQVIA in the 4th quarter worth about $27,000. Gilpin Wealth Management LLC acquired a new position in IQVIA in the 4th quarter worth about $27,000. CrossGen Wealth LLC acquired a new position in IQVIA in the 4th quarter worth about $28,000. Finally, Activest Wealth Management raised its holdings in IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock worth $31,000 after purchasing an additional 118 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.